Dose Optimization and Targeting Strategies of Anti-Infective Agents
Funding
Acknowledgments
Conflicts of Interest
References
- Huntjens, D.W.; Dijkstra, J.A.; Verwiel, L.N.; Slijkhuis, M.; Elbers, P.; Welkers, M.R.A.; Veldkamp, A.I.; Kuijvenhoven, M.A.; de Leeuw, D.C.; Abdullah-Koolmees, H.; et al. Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics 2023, 15, 163. [Google Scholar] [CrossRef] [PubMed]
- Katip, W.; Oberdorfer, P.; Kasatpibal, N. Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infection. Pharmaceutics 2022, 14, 1266. [Google Scholar] [CrossRef] [PubMed]
- Sima, M.; Bobek, D.; Cihlarova, P.; Rysanek, P.; Rousarova, J.; Berousek, J.; Kuchar, M.; Vymazal, T.; Slanar, O. Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin. Pharmaceutics 2022, 14, 1627. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Wu, M.; Diao, S.; Zhu, S.; Song, C.; Yue, J.; Martins, F.S.; Zhu, P.; Lv, Z.; Zhu, Y.; et al. Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination against New Delhi Metallo-beta-Lactamase and Serine-beta-Lactamase Co-Producing Escherichia coli and Klebsiella pneumoniae. Pharmaceutics 2023, 15, 251. [Google Scholar] [CrossRef] [PubMed]
- Hartinger, J.M.; Michalickova, D.; Dvorackova, E.; Hronova, K.; Krekels, E.H.J.; Szonowska, B.; Bednarova, V.; Benakova, H.; Kroneislova, G.; Zavora, J.; et al. Intraperitoneally Administered Vancomycin in Patients with Peritoneal Dialysis-Associated Peritonitis: Population Pharmacokinetics and Dosing Implications. Pharmaceutics 2023, 15, 1394. [Google Scholar] [CrossRef] [PubMed]
- Sima, M.; Hartinger, J.; Cikankova, T.; Slanar, O. Estimation of once-daily amikacin dose in critically ill adults. J. Chemother. 2018, 30, 37–43. [Google Scholar] [CrossRef] [PubMed]
- de Velde, F.; Mouton, J.W.; de Winter, B.C.M.; van Gelder, T.; Koch, B.C.P. Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives. Pharmacol. Res. 2018, 134, 280–288. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Šíma, M.; Slanař, O. Dose Optimization and Targeting Strategies of Anti-Infective Agents. Pharmaceutics 2023, 15, 1870. https://doi.org/10.3390/pharmaceutics15071870
Šíma M, Slanař O. Dose Optimization and Targeting Strategies of Anti-Infective Agents. Pharmaceutics. 2023; 15(7):1870. https://doi.org/10.3390/pharmaceutics15071870
Chicago/Turabian StyleŠíma, Martin, and Ondřej Slanař. 2023. "Dose Optimization and Targeting Strategies of Anti-Infective Agents" Pharmaceutics 15, no. 7: 1870. https://doi.org/10.3390/pharmaceutics15071870
APA StyleŠíma, M., & Slanař, O. (2023). Dose Optimization and Targeting Strategies of Anti-Infective Agents. Pharmaceutics, 15(7), 1870. https://doi.org/10.3390/pharmaceutics15071870